舒尼替尼治疗转移性肾癌的疗效和安全性分析：单中心37例总结  

Efficacy and safety of sunitinib in treating metastatic renal cell carcinoma., a single center 37 cases report

作　　者：吴翔[1] 李学松[1] 黄立华[1] 宋毅[1] 龚侃[1] 谌诚[1] 虞巍[1] 宋刚[1] 赵峥[1] 张争[1] 张骞[1] 王刚[1] 何志嵩[1] 周利群[1] 金杰[1] 

机构地区：[1]北京大学第一医院泌尿外科北京大学泌尿外科研究所国家泌尿男生殖系研究肿瘤中心,100034

出　　处：《中华泌尿外科杂志》2011年第4期278-281,共4页Chinese Journal of Urology

摘　　要：目的评价舒尼替尼治疗转移性肾细胞癌的疗效和安全性。方法2008年6月至2010年4月37例转移性肾细胞癌患者接受舒尼替尼治疗。其中男28例，女9例。年龄17～74岁，中位年龄52岁。行根治性肾切除手术33例，肾穿刺活检3例，腋窝转移淋巴结穿刺活检1例。von Hippel—Lindau综合征患者2例。肾透明细胞癌36例，其中伴颗粒细胞成分1例、伴肉瘤样分化4例，肾乳头状细胞癌1例。一线治疗30例，细胞因子或索拉非尼治疗进展后二线治疗7例。其中34例采用4／2方案，即口服舒尼替尼50．0mg／d4周，停用2周，6周为1个周期；3例予口服37．5mg／d持续治疗，直至疾病进展或者出现不可耐受的不良反应。结果中位随访时间12个月（8个周期）。34例患者治疗2周期以上，可进行疗效评估。根据RECIST标准评价最佳疗效，部分缓解9例（26．5％），疾病稳定24例（70．6％），疾病进展1例（2．9％）。客观反应率26．5％，疾病控制率97．1％。1年生存率95．8％（23／24），1年无进展生存率62．5％（15／24）。主要不良反应包括血小板减少30例（81．1％）、甲状腺功能异常18／22例（81．8％）、手足反应27例（73．0％）、白细胞减少23例（62．2％）、高血压18例（48．6％）等。大多数不良反应为1～2级，3级以上不良反应包括血小板降低8例（21．6％）、甲状腺功能异常4／22例（18．2％）、手足反应4例（10．8％）、血磷降低4例（10．8％）和腹泻2例（5．4％）等。10例（27．0％）在治疗过程中减量或停药，1例因严重乏力不能耐受终止治疗。通过对症支持，减量或停药，不良反应可控制并耐受。结论舒尼替尼一线及二线治疗晚期转移性肾细胞癌可取得较高的疾病控制率，不良反应发生率多数轻而易耐受，严重不良反应较少且可控。Objective To evaluate the efficacy and safety of sunitinib in the treatment of metastatic renal cell carcinoma （RCC）. Methods A total of 37 patients with metastatic RCC were treated with between June 2008 and April 2010, including 28 males and 9 females. The median age was 52 （17-74） years. All patients received a pathologic diagnosis of RCC, which consisted of 1 papillary cell carcinoma and 36 clear cell carcinomas, 4 of which accompanied with partial sarcoma differentiation. Thirty cases were treated with first line therapy and 7 cases showed progression on firstqine cytokine or sorafinib therapy. Sunitinib monotherapy was administered in repeated 6 week cycles of daily oral therapy for 4 weeks, followed by 2 weeks off in 34 patients, while another 3 patients received 37. 5 mg Qd continuously until disease progression or unacceptable toxicities occurred. Overall response rate and safety were evaluated. Results The median follow up was 12 months （8 cycles）,range 1.5- 19.5 months （1-13 cycles）. 26.5% （9/34） patients achieved partial responses, 70.6% （24/34） patients demonstrated stable disease over≥3 months and 1 （2.9%） patient developed pro gressive disease. The objective response rate was 26. 5%, and the disease control rate was 97. 1%. The 12 months＇ overall survival rate was 95. 8% （23/24）, and 12 months＇ progression free survival rate was 62.5 % （15/24）. The most common treatment-related adverse events were thrombocytopenia （30 cases, 81.1%）, thyroid dysfunction （18/22, 81.8%）,hand foot syndrome （27 eases, 73.0%）, neutropenia （23 cases, 62.2%） and hypertension （18 cases, 48.6%）. The major grade 3 adverse events included thrombocytopenia （8 cases, 21.6%）, hand foot syndrome （4 cases, 10.8%） and diar rhea （2 cases, 5. 4%）. Most adverse events were ameliorated by treatment interruption. Ten （27.0%） patients had dose decrement or drug discontinuation and 1 patient quit the treatment for intolerable fatigue. Conclusion The efficacy and

关 键 词：癌 肾细胞 肿瘤转移 舒尼替尼 治疗效果 存活率 

分 类 号：R737.11[医药卫生—肿瘤]